The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro by Lechler, Philipp et al.
RESEARCH ARTICLE Open Access
The antiapoptotic gene survivin is highly
expressed in human chondrosarcoma and
promotes drug resistance in chondrosarcoma
cells in vitro
Philipp Lechler
1*, Tobias Renkawitz
1, Valentina Campean
2, Sanjeevi Balakrishnan
3, Markus Tingart
4,
Joachim Grifka
1 and Jens Schaumburger
1
Abstract
Background: Chondrosarcoma is virtually resistant to chemotherapy and radiation therapy. Survivin, the smallest
member of the inhibitor of apoptosis protein family, is a critical factor for tumor progression and resistance to
conventional therapeutic approaches in a wide range of malignancies. However, the role of survivin in
chondrosarcoma has not been well studied. We examined the importance of survivin gene expression in
chondrosarcoma and analysed its influences on proliferation, apoptosis and resistance to chemotherapy in vitro.
Methods: Resected chondrosarcoma specimens from which paraffin-embedded tissues could be extracted were
available from 12 patients. In vitro experiments were performed in human chondrosarcoma cell lines SW1353 and
Hs819.T. Immunohistochemistry, immunoblot, quantitative PCR, RNA interference, gene-overexpression and analyses
of cell proliferation and apoptosis were performed.
Results: Expression of survivin protein was detected in all chondrosarcoma specimens analyzed, while
undetectable in adult human cartilage. RNA interference targeting survivin resulted in a G2/M-arrest of the cell
cycle and led to increased rates of apoptosis in chondrosarcoma cells in vitro. Overexpression of survivin resulted in
pronounced resistance to doxorubicin treatment.
Conclusions: These findings indicate that survivin plays a role in the pathogenesis and pronounced
chemoresistance of high grade chondrosarcoma. Survivin antagonizing therapeutic strategies may lead to new
treatment options in unresectable and metastasized chondrosarcoma.
Background
Chondrosarcomas comprise a heterogeneous group of
neoplasms characterized by the production of cartilage
matrix by malignant cells [1] and represent the third
most common primary malignancy of bone after mye-
loma and osteosarcoma [2]. Curative treatment of chon-
drosarcoma is restricted to surgical resection because of
pronounced resistance to chemotherapy and radiation
therapy [3-5]. The histological grade is directly related
to metastatic rate and remains currently the single
relevant predictor of patient outcome [6,7]. After ade-
quate resection, 10-year survival for patients with grade
I chondrosarcoma is excellent, whereas only 64% for
grade II and 29% for grade III tumors [8]. A large body
of evidence has demonstrated that chondrosarcoma’s
malignant phenotype and resistance to drug therapy is
favoured by constitutive activation of antiapoptotic path-
ways and loss of cell cycle control [9,10].
Survivin, the smallest member of the inhibitor of
apoptosis protein (IAP) family is reported to fulfil
important roles in cancer initiation, tumor progression
and drug/radiation resistance [11]. The molecular struc-
ture of survivin reveals one N-terminal baculovirus IAP
repeat (BIR) domain and a long C-terminal helix-coiled
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[12,13]. Extensive alternative splicing and a finely, by
transcriptional and post-transcriptional mechanisms,
controlled expression regulate survivin [14]. It is a
bifunctional protein that acts as a suppressor of cell
death and plays a key role in cell division. As a chromo-
somal passenger protein survivin accumulates to kineto-
chores at metaphase, localizes to the spindle mid-zone
at anaphase and is expressed in mid-bodies at telophase
[15,16]. While survivin is highly expressed in cancer and
during embryonal development it is said to be absent in
most adult differentiated organs. Thus, survivin appears
to be an ideal therapeutic target for cancer treatment
with little toxicity to normal tissues [17]. However, little
knowledge exists about expression of survivin in chon-
drosarcoma [18]. Here, we demonstrate, that the antia-
poptotic protein survivin is highly expressed in human
high grade chondrosarcoma and possibly acting as
a major factor for the tumor’sp r o n o u n c e dd r u g
resistance.
Methods
Unless otherwise stated all chemicals were purchased
from Sigma-Aldrich (Taufkirchen, Germany).
The study was approved by the Local Ethics Commit-
tee from the University of Regensburg (N° 09-131 and
N° 10-101-0170).
Collection of human tissues
Human chondrosarcoma tissues were collected from
radical tumorextirpation, either fixed in 4% para-formal-
dehyde (immunohistochemistry) or snap frozen
(immunoblot). Tumor specimens were analyzed by 2
independent pathologists. Histopathologic diagnosis and
tumor grade were confirmed by a national reference
pathologist. Detailed patient information can be found
on table 1.
Non-arthritic human cartilage of 6 Patients under-
going total knee replacement because of mono- or
bicompartmental osteoarthritis was collected. The
macroscopically and microscopically healthy chondral
layer of the unaffected compartment was harvested and
either snap frozen or fixed in 4% paraformaldehyde. The
mean donor age was 43 years (34 to 56 years). Written
informed consent was obtained from each patient.
Survivin immunohistochemistry
Survivin immunohistochemistry was performed as pre-
viously reported [19]. In short, paraffin-embedded speci-
mens were cut into 4 μm sections, dewaxed, and
rehydrated in ethanol. Endogenous peroxidase activity
was blocked by incubation with 10% H2O2/phosphate-
buffered saline at room temperature. Immunohisto-
chemical staining was performed according to a
commercial protocol based on a streptavidin-biotin-
peroxidase reaction (DAKO, Hamburg, Germany). For
antigen retrieval, sections were cooked for 20 minutes in
citrate buffer (pH 6.0) by using a standardized pressure
cooker (Biocare Medical, Walnut Creek, CA). Unspecific
signals were blocked by incubation with 5% fat-free
milk/phosphate-buffered saline for 1 hour at room tem-
perature. Next, sections were incubated with primary
antibodies overnight at 4°C. Thorough washing with
tris-buffered saline (50 mmol/L Tris-HCl and 136
mmol/L NaCl, pH 7.4) was followed by incubation with
biotinylated secondary antibody for 20 minutes. Subse-
quent to this the slides were incubated with avidin-
horseradish peroxidase and the DAB substrate. All incu-
bations were performed in a humidified chamber.
Between incubations, specimens were washed three
times in tris-buffered saline. All samples were processed
in parallel. Omission of primary antibody resulted in
completely negative signal. Hematoxylin solution
according to Gill was used to counterstain the slides.
Table 1 Clinicopathological details of tumor specimens
Patient Nr. Grade Location Origin Size (diameter in cm) Sex Age
1 I upper extremity peripheral 5 male 68
2 II costae central 6 male 53
3 II pelvis central 11 female 38
4 II upper extremity central 3 male 81
5 III lower extremity central 7 male 45
6 III lower extremity Central 5 female 78
7 III pelvis peripheral 7 male 65
8 III upper extremity central 4 female 52
9 III upper extremity unclassified 8 female 23
10 III costae central 6 female 78
11 III costae peripheral 4 male 65
12 III scapula unclassified 6 male 71
Clinicopathological data of the 12 chondrosarcomas regarding grade, location, origin, size, patient sex and age.
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was used to analyse and photograph the specimens. All
specimens were stained with rabbit polyclonal antibody
AF886 (R&D Systems, Wiesbaden, Germany) and were
confirmed with rabbit polyclonal antibody 500.201
(Novus Biologicals, Littleton, CO) and two mouse
monoclonal antibodies (clone 60.11 and clone 32.1,
Novus Biologicals). Details of all primary and secondary
antibodies used are given in table 2.
Cell line and culture conditions
For cell culture studies the human chondrosarcoma cell
lines SW1353 (also known as HTB-94) and Hs 819.T
(both obtained from American Type Culture Collection)
were cultured in Dulbecco’s Modified Eagle Medium
(PAA, Cölbe, Germany), supplemented with 10% fetal
calf serum, penicillin (50 U/ml) and streptomycin
(50 μg/ml). Cells were incubated at 37°C at 5% CO2 in
humidified air.
Survivin immunofluorescence
Chondrosarcoma cells were grown on glass slides and
fixed over 10 minutes in 3.7% Formalin/PBS at room
temperature. Next, sections were cooked for 20 minutes
in citrate buffer (pH 6.0, 10 mmol/l). The sections were
blocked with phosphatase-buffered saline and 5% fat-
free dried milk for 30 minutes at room temperature.
After incubation overnight with primary antibody at 4°C
and thorough washing with tris-buffered saline, tissues
were incubated with red fluorescent dye-labelled anti-
rabbit immunoglobulin (Invitrogen, Karlsruhe, Germany)
at 37°C for 1 hour. Finally, the nuclei were stained with
4,6-diamidino-2-phenylindole (6.5 g/ml; Invitrogen) for
10 minutes, and the stained sections were analysed and
photographed with a fluorescence microscope (Zeiss,
Jena, Germany).
Protein extraction and immunoblot analysis
Protein extraction of tissues and cells was performed as
previously described [20]. In brief, cell pellets and tis-
sues were homogenized into extraction buffer (7 mol/L
urea, 10% glycerol, 10 mmol/L Tris-HCl, pH 6.8, 1%
sodium dodecyl sulfate, 5 mmol/L dithiothreitol, 0.5
mmol/L phenylmethyl sulfonyl fluoride with 1 mg/L
aprotinin, pepstatin, and leupeptin) using a T8 Ultra-
Turrax homogenizer (IKA, Staufen, Germany). After
quantification, protein samples were run on 14%
polyacrylamide gels and transferred to Immobilon P
membranes (Millipore, Bedford, MA). Unspecific bind-
ing-sides were blocked with PBS and 5% fat-free dried
milk for 30 minutes at room temperature. Membranes
were probed with either polyclonal antibody AF886
(1:1000, R&D Systems) or monoclonal antibody NB500-
238 (clone 60.11, 1:500, Novus Biologicals) and horse-
radish peroxidase-conjugated secondary antibodies
(DAKO). Signals were visualized by chemiluminescence
(Pierce, Rockford, IL). Recombinant full-length human
survivin served as positive control (R&D Systems).
Survivin knockdown by siRNA
Knockdown of survivin was performed by the transfec-
tion of short interfering RNA (siRNA) as described in
[19,21,22]. The transfection of human survivin mRNA-
specific RNA oligonucleotides suppressed survivin
expression effectively at a concentration of 100 nmol/L
(suvivin 1). Knock down experiments were confirmed by
Table 2 Details of antibodies used
Method Detected
protein
Primary antibody Concentration
(μg/ml)
Secondary antibody Concentration
(μg/ml)
IHC Survivin pAB AF886 (R&D Systems) 5 Goat anti-rabbit immunoglobulin/biotinylated
(DAKO)
4
IHC Survivin mAB clone 32.1 (Novus
Biologicals)
6 Swine anti-mouse immunoglobulin/biotinylated
(DAKO)
4
IHC Survivin pAB 500.201 (Novus
Biologicals)
4 Goat anti-rabbit immunoglobulin/biotinylated
(DAKO)
4
IHC Survivin mAB clone 60.11 (Novus
Biologicals)
7 Swine anti-mouse immunoglobulin/biotinylated
(DAKO)
4
IF Survivin pAB AF886 (R&D Systems) 2 Red fluorescent dye-labeled anti-rabbit
immunoglobulin (Invitrogen)
1
IF Survivin mAB clone 60.11 (Novus
Biologicals)
2 Red fluorescent dye-labeled anti-mouse
immunoglobulin (Invitrogen)
1
IB Survivin pAB AF886 (R&D Systems) 1 Swine anti-rabbit immunoglobulins/HRP-conjugated
(DAKO)
0,2
IB Survivin mAB clone 60.11 (Novus
Biologicals)
2 Swine anti-mouse immunoglobulin/HRP-conjugated
(DAKO)
0,2
Primary and secondary antibodies used for immunohistochemistry, immunofluorescence, and immunoblotting are listed, with inclusion of sources, purpose, and
antibody concentrations. IB - immunoblot, IHC - immunohistochemistry, IF - immunofluorescence.
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(survivin 2) which resulted in similar reductions of sur-
vivin mRNA and protein levels. For negative controls,
siRNA targeting green fluorescence protein (GFP) was
transfected. 24 hours after knockdown cell cycle distri-
bution and apoptosis were analysed. Sequencences of
siRNAs used are given in Table 3.
Overexpression of survivin
Expression plasmid encoding wild type survivin was
generously provided by R. Stauber [23]. One day before
transfection, cells were plated at a density of ~50% and
expression plasmids were transfected into chondrosar-
coma cells using a commercially available transfection
reagent (FuGENE
® HD, Roche Applied Science,
Mannheim, Germany). Conditions according to the
manufacturer’s instructions. Transfection of pcDNA3
(Invitrogen) served as a negative control. The medium
was removed and replaced with full growth medium
6 hours after transfection. The cells were further incu-
bated at 37°C and 5% CO2 in humidified air. Transfec-
tion efficacy was controlled by immunoblot.
Cell Cycle Analysis
Both adherent and detached chondrosarcoma cells were
collected by trypsinization and washed with PBS for 5
minutes by centrifugation at 125 × g. Cells were resus-
pended in a staining solution containing 1.5 μmol/L
propidium iodide and 25 μg/ml RNase A and incubated
for 30 minutes in 37°C. The samples (10000 cells) were
analyzed by fluorescence-activated cell sorting with a
FACSCalibur (BD Biosciences, Heidelberg, Germany).
Caspase 3/7 Activity Assay
Apoptosis in chondrosarcoma cells in vitro was studied
by measuring the activity of caspases 3 and 7 using a
commercial kit (Caspase-Glo; Promega, Mannheim, Ger-
many). Cells were seeded in 6 well dishes at 1.5 × 10
5
per 3.5 cm well, 24 hours before knockdown was
performed. For analysis, 24 hours after knock down cells
were incubated for 90 minutes in a luciferase substrate
mix. Finally supernatant was removed and cells were
homogenized in lysate buffer. Buffer was transferred
into a 96-well microplate and luminescence activity was
measured in a luminometer (Berthold, Bad Wildbad,
Germany). Apoptosis was induced by 24 hours exposure
to doxorubicin (5 μM). This concentration resembles
the peak plasma level in oncologic patients receiving
doxorubicin based treatment regimens [24].
Measurement of cell viability by MTT
The viability of chondrosarcoma cells was measured by
methyl thiazolyl tetrazolium (MTT) assay. Cells were
plated onto 96-well plates at a density of 5000 cells per
well. 6 hours after transfection with specific siRNA or
plasmid, the serum-free medium was replaced by com-
plete medium. The transfection was repeated after
48 hours. MTT reagent (5 mg/ml) in 180 μlm e d i u m
was added at 0, 24, 48, 72 and 96 hours and incubated
for 4 hours at 37°C. Next, supernatant was removed and
150 μl dimethyl sulphoxide (DMSO) was added to each
well. After the plate was shaken on a rotary platform for
10 min, extinction at wavelength 490 nm was measured.
Measurement of cell proliferation
Cell proliferation of chondrosarcoma cells (SW1353 and
Hs819.T) was measured by analyzing BrdU incorpora-
tion into newly synthesized DNA using a commercially
available ELISA chemiluminescence assay (Roche Mole-
cular Biochemicals). Cells were plated out in 96-well
microtiterplates at a density of 5000 cells per well and
incubated for 24 hours prior the knock down of survivin
was performed. 24 after the transfection of specific
siRNA the cells were pulsed for BrdU incorporation
over 4 hours. ELISA was performed according to the
manufacturer’s instructions. Chemiluminescence values
(relative light units) were measured by an automated
luminometer (Berthold, Bad Wildbad, Germany).
RNA extraction and real-time PCR
Survivin mRNA expression was assayed by performing
real-time PCR as described in [19]. In short, RNA was
extracted by column purification using the RNeasy micro
kit (Qiagen, Hilden, Germany) and RNA transcribed into
cDNA. Survivin mRNA expression was detected by a set
of intron-spanning primer sequences for human survivin
(survivin 1) and was verified by the application of an
independent primer set (survivin 2). Control was human
b-actin. For primer details see table 4. All primers were
applied at a concentration of 300 nmol/L and 55°C
annealing temperature. A commercial 2× SYBR Green
PCR Mix (Eurogentec, Seraing, Belgium) was used
according to the manufacturer’si n s t r u c t i o n s .P C Rw a s
Table 3 Details of siRNA used
Gene Sense and antisense sequences Reference
Survivin 1 5’-CTTGGCCCAGTGTTTCTTCT-3’ [19,21]
5’-UGGCUCUUUCUCUGUCCAGTT-3’
Survivin 2 5’-GCGCCUGCACCCCGGAGCG-3’ [22]
5’-CGCUCCGGGGUGCAGGCGC-3’
GFP 5’-GGUGUGCUGUUUGGAGGUCTT-3’ [20]
5’-GAACUCCAAACAGCACACCTT-3’
RNA oligonucleotides with 3’-TT overhangs used for specific gene knockdown.
Target gene, sense and antisense sequences and references are listed. GFP -
green fluorescent protein.
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reaction with an end volume of 25 μl. Values for survivin
were related to their controls using the 2
-Δct calculation
method.
Statistics
At least three replicates for each experimental condition
were performed, and the presented results were repre-
sentative of these replicates. All values are presented as
means ± SEM. Student’s paired t-test was applied to
reveal statistical significances. P values less than 0.05
were considered significant. Statistical analyses were per-
formed using SPSS Software for Windows (version 13.0;
SPSS, Inc., Chicago, IL).
Results
Survivin is expressed in human chondrosarcoma
As a first step, we characterized survivin expression and
subcellular distribution in human chondrosarcoma by
immunohistochemistry. The staining of paraffin-
embedded samples revealed striking expression of survi-
vin protein in all chondrosarcomas analyzed (n = 12)
(Figure 1A and 1C). Higher magnification displays the
strong, predominantly cytoplasmatic subcellular distri-
bution of survivin protein (Figure 1B and 1D). In grade
III chondrosarcoma (n = 8), approximately 30% of visi-
ble nuclei stained positive for survivin protein. Impor-
tantly, cells displaying mitotic structures and tumor
giant cells displayed the strongest staining intensity
(Figure 1E). To ascertain the specificity of the pattern of
staining, we aimed to verify these findings with several
independent antibodies. Altogether, we confirmed the
result with two polyclonal (AF866 and pAB 500.201)
a n dt w om o n o c l o n a l( c l o n e3 2 . 1a n dc l o n e6 0 . 1 1 )a n t i -
bodies, where omission of primary antibody gave no sig-
nal (data not shown). To strengthen further the
evidence of survivin expression in chondrosarcoma we
aimed to verify protein expression with techniques other
than immunohistochemistry. Hence, tissue lysates of 3
high-grade chondrosarcomas (Patient Nr. 5, 7, 10)
showed specific signals for survivin protein by immuno-
blotting (Figure 1F). To ascertain the correct molecular
weight of 16.8 kDa, in vitro-transcribed and -translated
(IVTT) recombinant survivin protein was loaded.
Lysates of adult human articular cartilage (n = 6) served
as negative controls. Cartilage number 1 showed a faint
band at approximately 28 kDa and cartilage 2 revealed a
very weak band at 16.8 kDa. The macro- and microsco-
pically non-arthritic cartilage specimens were obtained
from patients undergoing total knee arthroplasty
because of mono- or bicompartmental osteoarthritis.
Survivin is expressed in human chondrosarcoma cells in
vitro and localizes to heterogenous subcellular
compartments
Having established that survivin is expressed in human
chondrosarcoma, we next examined the survivin expres-
sion characteristics in human chondrosarcoma cell line
SW1353. Survivin immunofluorescence of SW1353 cells
cultured on glass slide revealed a predominantly cyto-
plasmic localization (~65% of cells) of the protein, while
approximately 30% of cells displayed mixed cytoplasmic-
nuclear staining (Figure 2A-C). A minor fraction of cells
(<5%) showed a predominantly nuclear staining, which
may indicate imminent cell division (Figure 2D-F). In
less than 1% of cells mitotic structures like spindle appa-
ratus and midbody were seen (Figure 2G-I). Of note, the
staining intensity in these cells was by far higher com-
pared to the adjacent, interphasic cells. This finding is
consistent with preceding reports describing the mitotic
up-regulation of survivin mRNA and protein. Immuno-
fluorescence studies of the human chondrosarcoma cell
line Hs 819.T revealed a similar pattern of subcellular
survivin protein distribution (data not shown).
Knock-down of Survivin in chondrosarcoma cells results
in reduced rates of proliferation and a failure to exit
mitosis
After studying the subcellular localization of survivin
p r o t e i ni nc h o n d r o s a r c o m ac e l lin vitro,t h ef u n c t i o n a l
role of survivin was analysed by using RNA interference.
Transfection of survivin specific siRNA resulted in a sig-
nificant knockdown of survivin protein and mRNA in
SW1353 and Hs819.T cells (Figure 3A and 3B).
The influence of survivin on cell viability in SW1353
(Figure 4A left) and Hs819.T (Figure 4A right) was ana-
lysed by colorimetric measurement of methyl thiazolyl
tetrazolium uptake. Knock-down was performed at the
beginning of the experiment (0 hours) and repeated on
day 2 (48 hours). The MTT-assay revealed a significant
lower amount of viable cells 48 hours after the transfec-
tion of survivin-specific siRNA (Extinction 0.51, SEM
+/-0.03) in SW 1353 compared to the no siRNA control
(Extinction 0.64 SEM+/- 0.04). At 72 and 96 hours the
Table 4 Details of primers used for RT-PCR
Gene Forward and reverse primer sequences Reference
Survivin (1) 5’-AGTGAGGGAGGAAGAAGGCA-3’ [24]
5’-ATTCACTGTGGAAGGCTCTGC-3’
Survivin (2) 5’-CTTGGCCCAGTGTTTCTTCT-3’ [20]
5’-CCTCCCAAAGTGCTGGTATT-3’
ß-Actin 5’-AGTCCTGTGGCATCCACGAAA-3’ [20]
5’-GTCATACTCCTGCTTGCTGA-3’
Primer sets applied for the detection of survivin and b-Actin mRNA.
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Page 5 of 14Figure 1 Survivin expression in human chondrosarcoma. Immunohistochemistry and immunoblot for survivin (red staining) from human
chondrosarcoma specimens. A: Low-power image of human high-grade chondrosarcoma displays strong cellular expression of survivin protein.
B: High-power magnification reveals the predominantly cytoplasmic staining, although strong nuclear signals are detectable. C and D: Other
specimen of a grade III chondrosarcoma stained with monoclonal antibody, shows a similar pattern of staining. E: Strong survivin signal in a
tumor cell displaying a mitotic figure (arrow). F: To verify the expression of survivin in human chondrosarcoma, immunoblots were performed
from 3 high grade chondrosarcoma lysates (Patient Nr. 5, 7, 10). As control for the correct molecular weight, in vitro-transcribed and -translated
(IVTT) recombinant survivin protein, derived from the full-length human cDNA was loaded. Furthermore, lysates from adult human cartilage
served as a negative control. Total protein loaded was 1 μg for recombinant human survivin, 60 μg for chondrosarcoma and cartilage lysates.
For A, B and E the polyclonal rabbit anti-survivin antibody AF886 was used. For C and D the monoclonal mouse anti-survivin antibody clone 32.1
was used. Original magnifications: 200× (A and C) and 400× (B and D) and 600× (E).
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down was even more pronounced. Transfection of
green fluorescent protein (GFP) specific siRNA served
as an additional control and lead to no significant
alterations of the amount of viable cells (data not
shown). Analyzing the effects of survivin knock-down
in Hs 819.T revealed a similar tendency towards
reduction of measured cell viability (Figure 4A right).
To study survivin’s influence on cell proliferation in
SW 1353 (Figure 3B left) and Hs819.T (Figure 4B
right), BrdU incorporation was measured 24 hours
after the knock down of survivin. In both cell lines
the transfection of survivin specific siRNA led to
significantly (p < 0.05) reduced rates of proliferative
activity after 24 hours.
Cell cycle regulation and involvement in mitotic spindle
organization represent well characterized functions of survi-
vin in cancer cells, therefore 24 hours after siRNA transfec-
tion in SW1353 cell cultures, cell cycle distribution
was analyzed by propidium iodide staining and fluores-
cence-activated cell sorting (Figure 5). Suppression of survi-
vin resulted in a 2.1 fold increase (SEM+/- 0.3) of the
fraction of cells within G2/M phase of the cell cycle (Figure
5C). This failure to exit mitosis was previously shown in
other tumor cells and underlines survivin’si m p o r t a n tr o l ei n
cell division.
Figure 2 Survivin subcellular localization in human chondrosarcoma cells in vitro. Immunofluorescence localization of survivin using
chondrosarcoma cells (SW1353) cultured on glass slides (A,D,G) and 4,6-diamidino-2-phenylindole-staining (DAPI) of the identical positions (B,E,
H). Overlay of both stainings (C,F,I). A-C: The top row clearly shows the heterogeneous subcellular distribution from predominant cytoplasmic
(lower cell) in the majority of the cell population to mixed cytoplasmic-nuclear in a smaller fraction of cells (upper cell). D-F: In a premitotic cell,
survivin localizes to the mitotic spindle apparatus (arrow). Of note, here survivin signal appears stronger compared to the surrounding non-
mitotic cells. G-I: In late telophase the mid-body (arrow) stains positive for survivin protein. Original magnifications: 400× (A-I)
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apoptotic stimuli
In addition to cell cycle regulation and proliferation, we
assayed for influences of survivin on apoptosis by cas-
pase 3/7 activity (Figure 6A and 6C) and propidium
iodide staining and fluorescence-activated cell sorting
(Figure 6B and 6D). Apoptotic activity was studied
24 hours after survivin knock-down in SW1353 and
Hs819.T. Interfering with survivin’s function led to an
1.9 fold increase of caspase 3/7 activity and increased
the fraction of apoptotic SW 1353 cells 1.8 fold. Next,
we tested whether cellular stresses in combination with
survivin knockdown revealed a difference. Exposure to 5
μM doxorubicin increased the cellular fraction of apop-
totic SW 1353 cells approximately threefold (Figure 6A,
right) and caspase 3/7 activity by almost 3.8 fold (Figure
6B, right). Following survivin specific RNA interference
in SW 1353 cells doxorubicin exposure (5 μM ) resulted
in an 8.3 fold increase of the apoptotic fraction and 12.8
fold increase of caspase 3/7 activity. Next, effects of sur-
vivin knock down on apoptosis were analyzed in a sec-
ond cell line (Hs819.T). While isolated transfection of
survivin specific siRNA led to no significant changes in
caspase 3/7 activity (Figure 6C, left) or apoptotic frac-
tion (Figure 5D, left), after Doxorubicin exposure the
knock down significantly increased both apoptotic mar-
kers (Figure 6C and 6D, right).
Overexpression of survivin protects chondrosarcoma cells
against doxorubicin induced apoptosis, but shows no
effect on proliferation
Having established that down regulation of survivin gene
expression resulted in inhibition of proliferation and
increased rates of apoptosis, we next examined the effects
of survivin overexpression in SW1353 cells. Overexpres-
sion of survivin resulted in a marked upregulation of
detectable survivin protein after 24 and 48 hours. While,
transfection of empty plasmid (pcDNA3) showed no
changes in survivin protein levels (Figure 7A). First, pro-
liferation was analysed by employing the MTT -assay
( F i g u r e7 B ) .O v e r9 6h o u r s ,n os i g n i f i c a n ti n f l u e n c e so n
proliferation were seen at any point of time. Next,
we studied the effects of high levels of survivin on apop-
tosis by caspase 3/7 activity (Figure 7C) and propidium
iodide staining and fluorescence-activated cell sorting
(Figure 7D). Apoptotic activity was studied 24 hours after
Figure 3 Suppression of survivin expression by transfection of siRNA. RNA interference was performed in SW1353 and Hs 819.T, either for
GFP as control or for survivin. A: A pronounced decrease of survivin protein levels was measured by immunoblotting in SW1353 and Hs819.T. B:
Quantitative real time PCR confirmed the subtotal suppression of survivin expression in SW1353 (left) and Hs819.T (right).
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survivin led to no significant changes in the spontaneous
rate of apoptosis as shown by analysing apoptotic mar-
kers (Figure 7C and 7D, left). However, transfection of
survivin under cytotoxic conditions (5 μM doxorubicin)
reduced both, apoptotic fraction (1.6 fold, Figure 7C,
right) and caspase activity (2.2 fold, Figure 7D, right).
Discussion
Previous studies have shown that survivin, the smallest
member of the IAP protein family, has a bifunctional role
in cellular division and survival decisions. It is highly
expressed at mitosis and is a critical factor for completion
of mitotic cell division [15,16]. Survivin acts as a potent
inhibitor of apoptotic and non-apoptotic cell death, and
Figure 4 Influence of survivin knockdown on proliferation and cell viability distribution of chondrosarcoma cells. The influences of RNA
interference with survivin gene expression on cell viability and proliferation were measured by employing the MTT - assay (A) and by measuring
BrdU incorporation (B). A: Cell viability was analyzed by MTT assay. Knockdown of survivin was performed at 0 hours and repeated at 48 hours in
SW1353 (left) and Hs819.T (right). Significant reduction of viable cells compared to the untransfected control were seen in SW1353 after 48 hours
and in Hs819.T at 72 hours. Knockdown of GFP resulted in no significant alterations (Data not shown). The error bars represent +/-SEM. B:
Proliferation of chondrosarcoma cell lines SW1353 and Hs819.T was measured by BrdU incorporation and subsequent detection employing a
ELISA chemiluminescence immunoassay. Knock down was performed 24 hours prior to the incubation with BrdU. Knockdown of GFP resulted in
no significant alterations. The error bars represent +/-SEM. A: Original results of one representative experiment are shown. B: Original results of
three representative experiments are shown. P values less than 0.05 were considered significant (*).
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Page 9 of 14Figure 5 Effects of survivin knock down on cell cycle distribution in chondrosarcoma cells. SW1353 were transfected with siRNA targeting
survivin and cell cycle distribution was determined by PI staining and FACS analysis after 24 hours. Both attached and detached cells were
collected for the FACS analysis. GFP was transfected as control. Original dot blots and measured gates (left) and resulting histograms (right) are
shown. The second peak of the resulting histogram represents the G2/M-phase fraction. The original results of one representative experiment are
shown.
Lechler et al. BMC Cancer 2011, 11:120
http://www.biomedcentral.com/1471-2407/11/120
Page 10 of 14Figure 6 Influence of survivin knockdown on apoptotic rate of chondrosarcoma cells. Influences of RNA interference against survivin on
programmed cell death of SW1353 (A and B) and Hs819.T (C and D) were measured by caspase 3/7 activity (A and C) and by analysing the sub-
G0/1-phase fraction by using the fluorescence-activated cell sorting-propidium iodide staining method (B and D). Survivin knockdown resulted in
moderate elevations of the indicators of apoptotic activity in SW 1353 (A and B, left) but not in Hs819.T (C and D). Transfection of GFP had no
significant effects on apoptosis. Pronounced elevations of apoptotic markers were seen when the cells were stressed with doxorubicin 5 μM
over 24 hours (A - D, right). The cytotoxic treatment resulted in a substantial increase of caspase 3/7 activity and fraction of apoptotic cells.
Suppression of survivin sensitized the cells to doxorubicin treatment and further increased the apoptotic activity significantly in both cell lines.
Again, transfection of GFP siRNA was used as a control. The error bars represent +/-SEM. P values less than 0.05 were considered significant (*).
The original results of one representative experiment are shown.
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Page 11 of 14Figure 7 Influence of survivin overexpression on proliferation and apoptosis of chondrosarcoma cells in vitro.A :O v e r e x p r e s s i o no f
human full length survivin by transfection of plasmid DNA led to a significant increase of protein level, as measured by immunoblot. Empty
vector pcDNA3 was transfected as control. B: MTT - analysis over 5 days after transfection showed no influences on the proliferative activity of
SW1353. C and D: Overexpression of survivin resulted in no alterations of spontaneous apoptotic rate as measured by caspase 3/7 activity (C)
and by analysing the sub-G0/1-phase fraction by using the fluorescence-activated cell sorting-propidium iodide staining method (D). When
SW1353 cells were exposed for 24 hours to doxorubicin (5 μM) (right) the apoptotic fraction and caspase activity of not transfected and pcDNA3
transfected cells increased markedly. Transfection of survivin resulted in significantly reduced rates of apoptosis after cytotoxic treatment. The
error bars represent +/-SEM. P values less than 0.05 were considered significant (*). The original results of one representative experiment are
shown.
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Page 12 of 14protects cells as a stress response factor against unfavour-
able environments. From a clinical point of view, the most
interesting feature of survivin is the widely accepted con-
cept of an “oncofetal” pattern of expression. While unde-
tectable in most adult differentiated tissues, survivin is
ubiquitously expressed during embryonal developement
and highly re-expressed in cancer. In malignant tumors,
survivin antagonizes programmed cell death, favours
tumour-associated neovascularization, promotes cell pro-
liferation and preserves cell viability [11]. Disregarding the
yet undefined molecular mechanisms, a large body of evi-
dence has demonstrated that survivin has indeed a strong
potential of antagonizing drug and radiation induced
apoptosis [25,26]. In the current study, we report high
expression of survivin in human chondrosarcoma.
Furthermore, in vitro experiments indicate a potential role
in the tumor’s pronounced resistance to chemotherapy.
Our data shows homogeneous expression of survivin in all
analysed human chondrosarcomas (Figure 1A-D), while in
adult cartilage no or only low levels of survivin protein
were detectable (Figure 1 F). Immunohistochemistry
revealed a predominantly cytoplasmic pattern of staining
in chondrosarcoma. Immunofluorescence of cultured
chondrosarcoma cells confirmed the cytoplasmic subcellu-
lar localization of survivin protein (Figure 2), indicating
survivin’s involvement in extranuclear (i.e. proliferation
independent) functions. Of note, recent publications on
survivin emphasize the prognostic relevance of subcellular
distribution of survivin gene expression. While the prog-
nostic value of nuclear survivin expression in cancer
remains unclear, high levels of cytoplasmic survivin pro-
tein seem to correlate with resistance to drug/radiation
therapy and poor patient outcome [27,28]. The unfavour-
able prognosis related to cytoplasmic survivin might be
associated with its reported extranuclear function (e.g.
counteracting apoptosis), whereas nuclear survivin could
rather promote cell proliferation [29]. In this context it is
of particular interest that effects of strongly active proa-
poptotic substances as doxorubicin are significantly
reduced by survivin overexpression in SW1353 (Figure 7).
Accordingly, downregulation of survivin resulted in
increased rates of spontaneous and drug induced apopto-
sis (Figure 6). It is therefore tempting to speculate that
survivin represents a key molecule in maintaining consti-
tutive antiapoptotic activity in chondrosarcoma. In this
context, it has been shown, that an upregulation of survi-
vin protein did not increase cell proliferation or changed
cell cycle distribution, while suppression of survivin
resulted in a failure to exit mitosis, the previously
described G2/M-arrest [21].
Conclusions
In summary, we demonstrate that the antiapoptotic pro-
tein survivin is highly expressed in human high grade
chondrosarcoma. Functional analyses in chondrosar-
coma cells in vitro indicate that survivin exerts the clas-
sic functions of cell cycle regulation and survival control
in human chondrosarcoma. Moreover, our findings indi-
cate that survivin might be a potent promoter of resis-
tance to chemotherapeutic agents in chondrosarcoma.
Still, the role of survivin in oncogenesis and the rele-
vance of its predominantly cytoplasmic distribution in
human chondrosarcoma remain elusive.
Learning more about survivin’s role in chondrosar-
coma and evaluating the effects of survivin-antagonizing
therapeutic strategies will be an important task for
future studies.
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